Rachael Busch, NP
Family · Loxahatchee, FLNPI 1063819589
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,600 of the $188,760 with a category attached, or 74.5%. 38 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 26.7% of the total. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,202 payments — averaging $157.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$50K
- Amgen$44K
- Johnson & Johnson$23K
- Pfizer$17K
- Boehringer Ingelheim$15K
- AstraZeneca$9K
- plus $30K from 32 others
What the payments were for
- Consulting fees$14,1517%
- Speaking & faculty fees$140,60074%
- Travel & lodging$10,0645%
- Food & beverage$23,68813%
- Education$2570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 129 | $50,312 |
| Amgen(2 entities) | 209 | $44,337 |
| Johnson & Johnson(2 entities) | 90 | $23,450 |
| Pfizer | 76 | $17,114 |
| Boehringer Ingelheim | 52 | $14,504 |
| AstraZeneca(2 entities) | 80 | $9,066 |
| ANI Pharmaceuticals, Inc. | 66 | $6,128 |
| UCB, Inc. | 125 | $4,817 |
| Sobi, Inc | 16 | $4,573 |
| Lilly USA, LLC | 28 | $4,532 |
| Novartis | 102 | $3,253 |
| Janssen Scientific Affairs, LLC | 8 | $1,509 |
| AbbVie | 58 | $1,278 |
| Sanofi | 17 | $793 |
| GSK | 36 | $707 |
| E.r. Squibb & Sons, L.L.C. | 22 | $327 |
| Radius Health, Inc. | 14 | $272 |
| Kyowa Kirin, Inc. | 7 | $226 |
| Actelion Pharmaceuticals US, Inc. | 6 | $199 |
| Recordati_rare_diseases_inc. | 6 | $173 |
| Aurinia Pharma U.S., Inc. | 8 | $155 |
| Fresenius Kabi USA, LLC | 7 | $153 |
| Scilex Pharmaceuticals Inc. | 6 | $133 |
| Alvogen Inc | 5 | $106 |
| Neurometrix Inc | 1 | $100 |
| Genentech USA, Inc. | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Organon | 8 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $43 |
| Invivyd Inc | 2 | $34 |
| Vertex | 1 | $30 |
| Abbott | 1 | $23 |
| Mylan Institutional Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$188,760 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel MiniEtanercept | 32 | $262,023 |
| RinvoqUpadacitinib | 22 | $139,786 |
| Humira(Cf) PenAdalimumab | 19 | $126,626 |
| Enbrel SureclickEtanercept | 16 | $117,090 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $107,717 |
| Humira PenAdalimumab | 13 | $90,196 |
| XeljanzTofacitinib Citrate | 13 | $86,105 |
| Mycophenolate Mofetil | 46 | $8,615 |
| Hydroxychloroquine Sulfate | 188 | $5,875 |
| Leflunomide | 87 | $4,857 |
| Gabapentin | 247 | $3,472 |
| MethotrexateMethotrexate Sodium | 188 | $3,432 |
| Cevimeline Hcl | 25 | $3,283 |
| Colchicine | 31 | $2,948 |
| Duloxetine Hcl | 87 | $2,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,278 | $139,78622 claims |
| UCB, Inc.Cimzia (2 Pack) | $4,817 | $107,71713 claims |
| PfizerXeljanz | $17,114 | $86,10513 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $133 | $2,94831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Loxahatchee
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
- Kathleen WilsonTallahassee$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.